Portside Wealth Group LLC Takes Position in Boston Scientific Corporation $BSX

Portside Wealth Group LLC acquired a new position in shares of Boston Scientific Corporation (NYSE:BSX) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 21,859 shares of the medical equipment provider’s stock, valued at approximately $2,134,000.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Steph & Co. bought a new stake in shares of Boston Scientific in the 3rd quarter valued at about $25,000. Financial Consulate Inc. bought a new position in shares of Boston Scientific during the 3rd quarter worth approximately $25,000. FWL Investment Management LLC purchased a new stake in Boston Scientific during the second quarter valued at approximately $26,000. United Community Bank boosted its stake in Boston Scientific by 115.7% in the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 147 shares in the last quarter. Finally, Kilter Group LLC purchased a new position in Boston Scientific in the second quarter worth $30,000. Institutional investors own 89.07% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares in the company, valued at $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the sale, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,396,580. The trade was a 42.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.50% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts have recently commented on BSX shares. Needham & Company LLC reiterated a “buy” rating on shares of Boston Scientific in a report on Thursday, January 15th. National Bankshares set a $115.00 target price on Boston Scientific in a research report on Monday. TD Cowen reiterated a “buy” rating on shares of Boston Scientific in a research note on Monday. Weiss Ratings reissued a “buy (b-)” rating on shares of Boston Scientific in a report on Wednesday, January 21st. Finally, Wall Street Zen upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, Boston Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $121.84.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q4 beat on both EPS and revenue; revenue grew ~15.9% year-over-year, and margins improved — the underlying quarter was strong, showing continued organic growth across several franchises. Boston Scientific announces results for fourth quarter and full year 2025
• Neutral Sentiment: Analyst coverage and the company’s earnings materials/earnings call provide detail for valuation and segment trends — useful for investors who want to dig into segment-level drivers and management’s assumptions. Q4 2025 Earnings Call Transcript
• Negative Sentiment: Management’s FY‑2026 guidance was modestly below or roughly in line with Street expectations (FY EPS range and revenue range came in light enough to reset growth assumptions), and Q1 guidance was cautious — that outlook is the main driver of the selloff. Boston Scientific shares slide on cautious 2026 revenue forecast
• Negative Sentiment: Electrophysiology (one of Boston Scientific’s higher-growth, higher-profile segments) underperformed vs. expectations, which worried investors about near-term growth momentum in a key franchise. Boston Scientific hits an 18-month low on a ‘sore spot’ for its most hyped device
• Negative Sentiment: Unusually large put-option activity and heavy trading signaled short-term bearish positioning and hedging, amplifying downside pressure. BSX Earnings: Boston Scientific Stock Plunges on Weak Guidance
• Negative Sentiment: CEO insider selling (large block disclosed) adds to near-term negative sentiment even though insider transactions can be for many reasons. Insider sale SEC filing

Boston Scientific Trading Down 17.6%

Shares of NYSE:BSX opened at $75.50 on Thursday. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47. Boston Scientific Corporation has a 52-week low of $75.00 and a 52-week high of $109.50. The stock has a market cap of $111.92 billion, a price-to-earnings ratio of 40.37, a PEG ratio of 1.63 and a beta of 0.67. The business has a 50-day moving average price of $94.37 and a 200-day moving average price of $99.13.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The company had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. During the same quarter in the prior year, the company earned $0.70 EPS. Boston Scientific’s quarterly revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Equities analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.